Los Angeles Times: Clinical Data on Stem Cell Efficacy from Gallant

Gallant was featured in The Los Angeles Times for its investigational allogeneic stem cell therapy for feline chronic gingivostomatitis (FCGS), a severe and often treatment-resistant inflammatory oral disease in cats. The coverage highlights findings from a recent clinical field study evaluating Gallant’s uterine-derived mesenchymal stem cell (UMSC) therapy.

The article outlines how many cats with refractory FCGS continue to experience significant pain and inflammation despite full-mouth extractions and conventional therapies. Study results demonstrated meaningful improvements in quality of life for a majority of treated cats, with early response observed in some patients and a favorable safety profile.

The Los Angeles Times also notes the potential for earlier intervention to support improved healing outcomes, underscoring Gallant’s commitment to developing FDA-regulated, ready-to-use regenerative therapies designed to integrate seamlessly into everyday veterinary practice and improve long-term health outcomes for pets.

From the Los Angeles Times
Feline Chronic Gingivostomatitis: Clinical Data on Stem Cell Efficacy from Gallant